AMPIO PHARMACEUTICALS, INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.ampiopharma.com
Clinical Trials
17
Active:0
Completed:13
Trial Phases
3 Phases
Phase 1:5
Phase 2:6
Phase 3:6
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (17 trials with phase data)β’ Click on a phase to view related trials
Phase 2
6 (35.3%)Phase 3
6 (35.3%)Phase 1
5 (29.4%)A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)
Phase 1
Completed
- Conditions
- Covid19
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04880161
- Locations
- πΊπΈ
Ampio Pharmaceuticals, Englewood, Colorado, United States
A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19
Phase 2
Terminated
- Conditions
- Covid19
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT04868890
- Locations
- πΊπΈ
Ampio Pharmaceuticals, Englewood, Colorado, United States
Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen
Phase 2
Terminated
- Conditions
- COVID-19
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04839965
- Locations
- πΊπΈ
Ampio Pharmaceuticals, Englewood, Colorado, United States
Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress
Phase 1
Completed
- Conditions
- Covid19
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04606784
- Locations
- πΊπΈ
Research Site, Colorado Springs, Colorado, United States
Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation
Phase 1
Completed
- Conditions
- COVID-19
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04456452
- Locations
- πΊπΈ
Research Site, Colorado Springs, Colorado, United States
- Prev
- 1
- 2
- 3
- Next
News
No news found